HC Wainwright restated their buy rating on shares of CalciMedica (NASDAQ:CALC – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 target price on the stock.
CalciMedica Stock Up 3.2 %
Shares of CALC opened at $2.27 on Tuesday. The business’s 50 day moving average is $2.78 and its two-hundred day moving average is $3.46. CalciMedica has a 52-week low of $1.86 and a 52-week high of $6.27. The firm has a market cap of $30.60 million, a price-to-earnings ratio of -2.10 and a beta of 1.18.
Hedge Funds Weigh In On CalciMedica
A number of institutional investors have recently made changes to their positions in CALC. Atria Investments Inc raised its position in shares of CalciMedica by 136.5% in the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after purchasing an additional 15,296 shares in the last quarter. Geode Capital Management LLC raised its position in shares of CalciMedica by 51.2% in the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after purchasing an additional 22,525 shares in the last quarter. PVG Asset Management Corp acquired a new stake in shares of CalciMedica during the 3rd quarter valued at approximately $67,000. Corient Private Wealth LLC acquired a new stake in shares of CalciMedica during the 4th quarter valued at approximately $135,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of CalciMedica during the 4th quarter valued at approximately $153,000.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Stories
- Five stocks we like better than CalciMedica
- What is a buyback in stocks? A comprehensive guide for investors
- GitLab: Get In While It’s Down—Big Rebound Ahead
- The 3 Best Fintech Stocks to Buy Now
- Tesla Stock: Finding a Bottom May Take Time
- 3 REITs to Buy and Hold for the Long Term
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
